• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贫血与局部晚期头颈癌患者生存率降低及局部区域复发增加相关:RTOG 85-27的二次分析

Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.

作者信息

Lee W R, Berkey B, Marcial V, Fu K K, Cooper J S, Vikram B, Coia L R, Rotman M, Ortiz H

机构信息

Wake Forest University School of Medicine, Winston-Salem, NC 27157-1030, USA.

出版信息

Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1069-75. doi: 10.1016/s0360-3016(98)00348-4.

DOI:10.1016/s0360-3016(98)00348-4
PMID:9869231
Abstract

PURPOSE

The purpose of the present study is to investigate the strength of association between anemia and overall survival, locoregional failure, and late radiation therapy (RT) complications in a large prospective study of patients with advanced head and neck cancer treated with conventional radiotherapy with or without a hypoxic cell sensitizer.

METHODS AND MATERIALS

Between March 1988 and September 1991, 521 patients with Stage III or IV squamous cell carcinoma of the head and neck were entered into a randomized trial examining the addition of etanidazole (SR 2508) to conventional radiation therapy (RT) (66-74 Gy in 33-37 fractions, 5 days a week). Patients with hemoglobin (Hgb) levels measured and recorded prior to the second week of RT were included in this secondary analysis. Hemoglobin levels were stratified as normal (> or = 14.5 gm% for men, > or = 13 gm% for women) or anemic (< 14.5 gm% for men, < 13 gm% for women). Locoregional failure rates were calculated using the cumulative incidence approach. Overall survival was estimated according to the Kaplan-Meier method. Late RT toxicity was scored according to the RTOG morbidity scale. Differences in rates of overall survival, locoregional failure, and late complications were tested by the Cox proportional hazard model.

RESULTS

Of 504 eligible patients, 451 had a Hgb level measured and recorded prior to the second week of RT. One hundred sixty-two patients (35.9%) were considered to have a normal Hgb level and 289 patients (64.1%) were considered to be anemic. The estimated survival rate is 35.7% at 5 years in patients with a normal Hgb, versus 21.7% in anemic patients (p = 0.0016). The estimated locoregional failure rate is 51.6% at 5 years in patients with a normal Hgb, versus 67.8% in anemic patients (p = 0.00028). The estimated rate of grade 3 or greater toxicity is 19.8% at 5 years in patients with a normal Hgb, versus 12.7% in anemic patients (p = 0.063). On multivariate analysis, several variables were found to be independent predictors of survival including: T stage, Karnofsky performance status, N stage, age, total radiation dose to the primary, and Hgb level. Independent predictors of locoregional control included T stage, Karnofsky performance status, N stage, radiation dose, and Hgb level. The only variables which predicted for the development of late RT complications were gender (p = 0.0109) and age (p = 0.0167). These findings were consistent regardless of whether Hgb level was considered a dichotomous or continuous variable.

CONCLUSION

Low Hgb levels are associated with a statistically significant reduction in survival and an increase in locoregional failure in this large prospective study of patients with advanced head and neck cancer. Hgb level should be considered as a stratification variable in subsequent studies of head and neck cancer. Strategies to increase Hgb prior to RT in patients with head and neck cancer may lead to improved survival and loco-regional control.

摘要

目的

本研究旨在通过一项大型前瞻性研究,探讨晚期头颈癌患者在接受常规放疗(无论是否联合使用乏氧细胞增敏剂)时,贫血与总生存期、局部区域复发以及放疗晚期并发症之间的关联强度。

方法与材料

1988年3月至1991年9月期间,521例Ⅲ期或Ⅳ期头颈鳞状细胞癌患者进入一项随机试验,该试验旨在研究在常规放疗(66 - 74 Gy,分33 - 37次,每周5天)基础上加用依他硝唑(SR 2508)的效果。本次二次分析纳入了放疗第二周前测量并记录血红蛋白(Hgb)水平的患者。血红蛋白水平分为正常(男性≥14.5 g%,女性≥13 g%)或贫血(男性<14.5 g%,女性<13 g%)。局部区域复发率采用累积发病率法计算。总生存期根据Kaplan - Meier方法估算。放疗晚期毒性按照RTOG发病率量表评分。总生存期、局部区域复发率和晚期并发症发生率的差异通过Cox比例风险模型进行检验。

结果

在504例符合条件的患者中,451例在放疗第二周前测量并记录了Hgb水平。162例患者(35.9%)Hgb水平正常,289例患者(64.1%)为贫血。Hgb水平正常患者的5年估计生存率为35.7%,贫血患者为21.7%(p = 0.0016)。Hgb水平正常患者的5年局部区域复发估计率为51.6%,贫血患者为67.8%(p = 0.00028)。Hgb水平正常患者的5年3级及以上毒性估计率为19.8%,贫血患者为12.7%(p = 0.063)。多因素分析发现,包括T分期、卡氏功能状态评分、N分期、年龄、原发灶总放疗剂量和Hgb水平在内的多个变量是生存的独立预测因素。局部区域控制的独立预测因素包括T分期、卡氏功能状态评分、N分期、放疗剂量和Hgb水平。预测放疗晚期并发症发生的唯一变量是性别(p = 0.0109)和年龄(p = 0.0167)。无论将Hgb水平视为二分变量还是连续变量,这些结果均一致。

结论

在这项大型晚期头颈癌患者前瞻性研究中,低Hgb水平与生存的统计学显著降低及局部区域复发增加相关。在后续头颈癌研究中,Hgb水平应被视为分层变量。提高头颈癌患者放疗前Hgb水平的策略可能会改善生存和局部区域控制。

相似文献

1
Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.贫血与局部晚期头颈癌患者生存率降低及局部区域复发增加相关:RTOG 85-27的二次分析
Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1069-75. doi: 10.1016/s0360-3016(98)00348-4.
2
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.一项RTOG III期试验(RTOG 85-27)的结果,该试验比较了放疗联合乙硝唑与单纯放疗用于局部晚期头颈癌的疗效。
Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):567-76. doi: 10.1016/0360-3016(95)00150-W.
3
Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.治疗前贫血与晚期头颈癌放疗及同步化疗疗效降低相关。
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1087-95. doi: 10.1016/j.ijrobp.2004.07.710.
4
Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy--a secondary analysis of three consecutive clinical phase III trials.血红蛋白水平与接受放疗的局部晚期食管癌患者发病率和死亡率的关联——三项连续临床III期试验的二次分析
Clin Oncol (R Coll Radiol). 2006 Oct;18(8):621-7. doi: 10.1016/j.clon.2006.04.015.
5
Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.晚期头颈癌加速分割放疗方案两种变体的随机I/II期试验:RTOG 88-09的结果
Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):589-97. doi: 10.1016/0360-3016(95)00078-D.
6
[SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].同步放化疗联合顺铂治疗局部晚期头颈部鳞状细胞癌(SCHNC)。早期结果及毒性评估
Otolaryngol Pol. 2011 Sep;65(5 Suppl):117-25. doi: 10.1016/S0030-6657(11)70719-3.
7
The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck.贫血对头颈部局部晚期鳞状细胞癌放疗后疗效及正常组织毒性的影响。
Radiother Oncol. 2003 Aug;68(2):113-22. doi: 10.1016/s0167-8140(03)00198-1.
8
Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).同期顺铂和超分割放疗局部晚期头颈部癌:随机 III 期试验(SAKK 10/94)的 10 年随访结果。
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):524-31. doi: 10.1016/j.ijrobp.2010.11.067. Epub 2011 Feb 16.
9
Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck.放射肿瘤学组9903的长期结果:一项评估促红细胞生成素对接受放射治疗的头颈部鳞状细胞癌贫血患者局部区域控制效果的随机3期试验。
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):907-15. doi: 10.1016/j.ijrobp.2014.12.018. Epub 2015 Feb 7.
10
Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck.局部晚期头颈部鳞状细胞癌的加速放疗联合延迟同步推量放疗
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):589-95. doi: 10.1016/s0360-3016(99)00218-7.

引用本文的文献

1
Pre-treatment anemia in head and neck cancer: risk factors, subtypes, and survival outcomes.头颈癌的治疗前贫血:危险因素、亚型及生存结果
Front Oncol. 2025 Jun 25;15:1577901. doi: 10.3389/fonc.2025.1577901. eCollection 2025.
2
Repurposing radiosensitising medicines for radiotherapy: an overview.将放射增敏药物重新用于放射治疗:概述
BMJ Oncol. 2024 Jan 17;3(1):e000192. doi: 10.1136/bmjonc-2023-000192. eCollection 2024.
3
Blood- and Imaging-Derived Biomarkers for Oncological Outcome Modelling in Oropharyngeal Cancer: Exploring the Low-Hanging Fruit.
用于口咽癌肿瘤学结局建模的血液和影像衍生生物标志物:探索唾手可得的成果。
Cancers (Basel). 2023 Mar 28;15(7):2022. doi: 10.3390/cancers15072022.
4
Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation.定义治疗前血红蛋白水平作为头颈部癌患者接受放化疗的生存结果的生物标志物的最佳阈值和预后效用。
Oral Oncol. 2022 Oct;133:106054. doi: 10.1016/j.oraloncology.2022.106054. Epub 2022 Aug 5.
5
Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer.肛管癌的长期临床结局及无进展生存期的相关预测因素
J Gastrointest Oncol. 2022 Feb;13(1):185-196. doi: 10.21037/jgo-21-482.
6
Experimental Drugs for Chemotherapy- and Cancer-Related Anemia.用于化疗及癌症相关贫血的实验性药物。
J Exp Pharmacol. 2021 Jun 24;13:593-611. doi: 10.2147/JEP.S262349. eCollection 2021.
7
Anemia of Chronic Diseases: Wider Diagnostics-Better Treatment?慢性病贫血:更广泛的诊断——更好的治疗?
Nutrients. 2020 Jun 16;12(6):1784. doi: 10.3390/nu12061784.
8
Hemoglobin Levels and Red Blood Cells Distribution Width Highlights Glioblastoma Patients Subgroup With Improved Median Overall Survival.血红蛋白水平和红细胞分布宽度凸显出胶质母细胞瘤患者中总生存期中位数有所改善的亚组。
Front Oncol. 2020 Apr 17;10:432. doi: 10.3389/fonc.2020.00432. eCollection 2020.
9
Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation.贫血和中性粒细胞与淋巴细胞比值对接受同步放化疗的p16阳性口咽癌具有预后价值。
Papillomavirus Res. 2018 Jun;5:32-37. doi: 10.1016/j.pvr.2017.12.002. Epub 2017 Dec 11.
10
Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy -- design of the DAHANCA 31 randomized trial.头颈部癌患者同步放化疗期间的渐进性抗阻训练——DAHANCA 31随机试验设计
BMC Cancer. 2017 Jun 3;17(1):400. doi: 10.1186/s12885-017-3388-0.